Eric A. Klein, MD, discusses the role of genomic testing in patients with prostate cancer and how these findings can impact treatment decisions.
Eric A. Klein, MD, chairman, Glickman Urological & Kidney Institute, and staff member, Taussig Cancer Institute, Cleveland Clinic, discusses the role of genomic testing in patients with prostate cancer and how these findings can impact treatment decisions.
Like with many other cancer tumors, there are tools available to evaluate the genome of prostate cancers, says Klein. One way to look at this is to focus on men with metastatic disease where genotyping the metastatic tumor can dictate treatment. For example, rucaparib (Rubraca) was approved by the FDA and can be used to treat patients with a BRCA mutation. This PARP inhibitor has been shown to improve survival in this setting.
A few years ago, there were 4 agents available on the market, which helped determine molecular aggressiveness of early-stage prostate cancer, according to Klein. Genomic testing helps determine clinical decision making in terms of deciding who is a good candidate for active surveillance, says Klein. Physicians need to know who may need to be treated because of a worrisome cancer hiding in the prostate cancer that was missed by an initial biopsy and who may benefit from early radiation therapy after a radical prostatectomy.
Peritoneal RFS May Be a Stronger Predictor of OS in CRC Peritoneal Metastasis
March 27th 2024In an interview with Targeted Oncology, Muhammad Talha Waheed, MBBS, discussed research on the reliability of using recurrence-free survival as an efficacy end point for trials evaluating patients with colorectal cancer peritoneal metastasis.
Read More
Integrating New Therapies With Autologous Stem Cell Transplant in Myeloma
March 26th 2024Saad Z. Usmani, MD, MBA, FACP, FASCO, discussed how the role of autologous stem cell transplant is evolving in the myeloma treatment landscape with the emergence of CAR T-cell therapies and bispecifics.
Read More